Compare relapse clinical severity , post-relapse residual disability , and the probability of confirmed complete recovery from relapse between patients who relapsed during natalizumab ( n = @/@ -LSB- @ % -RSB- ) and placebo ( n = @/@ -LSB- @ % -RSB- ) treatments in the AFFIRM trial .